| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Using the quantitative method of high sensitivity mass spectrometry for sphingolipid, healthy subjects and blood sphingolipid of each cancer patient was analyzed quantitatively. Especially, it was investigated clinical applicability as a novel tumor marker of SlP. Plasma S1P concentrations were 410±67 nM, 620±129 nM, 484±151 nM, and 491±106 nM in healthy, esophageal cancer, stomach cancer, sarcoma, respectively. Esophageal cancer patient plasma S1P concentration was for the first time revealed that it is significantly higher compared to the healthy subjects. Using metabolome analysis profiling for cancer disease analysis as some new biomarker candidates, in particular, I found the possibility of cystine.
|
